Aerovate stockholders approve merger with Jade Biosciences, 1-for-35 reverse split

Jade Biosciences, Inc.

All eight proposals approved at April 16 special meeting, including merger and reverse stock split.
Board approves 1-for-35 reverse split, reducing outstanding from ~30M to ~0.8M shares.
Special cash dividend of $69.6M ($2.40/share) unaffected; record date April 25.
Combined company to trade as JBIO on Nasdaq starting April 29 after merger close.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.